Evidence map›Paper›PMID 20501950›Full record

ArticleThe Journal of clinical investigation2010

Gazing into a crystal ball to predict kidney transplant outcome.

Bernd Schröppel, Peter S Heeger

Registry-linked trialOpen access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01338779 (Identification and Mechanistic Investigations of Tolerant Transplant Recipients), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01338779 completednot on this map

Identification and Mechanistic Investigations of Tolerant Transplant Recipients

TypeobservationalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2004 to 2015Enrolled197ConditionsTransplant Rejection, Kidney Transplantation, Renal Transplantation, Renal Transplant
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Identifying biomarkers as diagnostic tools in kidney transplantation.Expert review of molecular diagnostics · 2011
    Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Bernd SchröppelMount Sinai School of Medicine, New York, New York 10029, USA.
Peter S Heeger
Icahn School of Medicine at Mount Sinai · US

Funding

Noninvasive Markers and Transplant Outcome in HumansU01AI063594 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HEEGER, PETER SCOTT · 2004 to 2022
$66.5M
Contribution of Toll-like receptor signaling in islet transplantationK08AI071038 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHROPPEL, BERND · 2007 to 2010
$618k
NIAID NIH HHS K08 AI 071038NIAID NIH HHS K08 AI071038NIAID NIH HHS U01 AI063594NIAID NIH HHS U01 AI63594-01
6 · The paper itself

Abstract

Kidney transplantation is the optimal therapy for end-stage kidney disease but requires lifelong immunosuppression. Despite improvements in immunosuppression regimens that have reduced rates of acute transplant rejection, long-term allograft survival remains suboptimal. More than 50% of transplanted kidneys from deceased donors fail within 10 years. In order to improve long-term outcomes, physicians need to better understand mechanisms underlying transplant rejection and tolerance in humans. They also need biomarkers that differentiate patients likely to maintain excellent and stable allograft function from recipients at risk of losing their transplants. By studying kidney transplant recipients at high risk for graft loss and rare, spontaneously tolerant kidney transplant recipients, researchers reporting in 3 papers in this issue of the JCI shed new light on these topics.

Indexed as

Kidney TransplantationTreatment OutcomeGraft RejectionHumansImmunosuppression TherapyKidneyKidney Failure, ChronicTissue Donors

Identifiers

PMID20501950
PMCPMC2877963
OpenAlexW2161726667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.